首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1746583

日本蛋白质治疗市场报告（按产品（单株抗体、人类胰岛素、促红血球生成素、凝血因子、融合蛋白等）、治疗领域、功能和地区划分）2025 年至 2033 年

Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本蛋白质疗法市场规模达303亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到538亿美元，2025-2033年期间的复合年增长率（CAGR）为6.27%。癌症、糖尿病和自体免疫疾病等慢性疾病发生率的上升，导致对蛋白质疗法的需求增加，从而提供有针对性的、有效的治疗，从而推动市场发展。

蛋白质疗法是指利用蛋白质（通常是生物衍生的分子）来预防、控製或治疗各种疾病和病症的一类医疗手段。这些治疗性蛋白质包括抗体、酵素、荷尔蒙或其他在人体生物过程中发挥关键作用的功能性蛋白质。蛋白质疗法旨在针对特定的疾病机制，例如与癌细胞结合或调节免疫反应，与传统药物相比，其精准度更高且副作用更少。它们通常采用包括重组DNA技术在内的生物技术生产，并可透过注射、输注或其他给药方式给药。蛋白质疗法的例子包括用于治疗类风湿性关节炎等自体免疫疾病的单株抗体、用于治疗糖尿病的胰岛素以及用于治疗血友病的凝血因子。这些疗法彻底改变了医学，为多种疾病提供了有效的治疗方法，并透过持续的研发努力不断取得进展。

日本蛋白质治疗市场趋势：

日本蛋白质疗法市场蓬勃发展，得益于几个关键驱动因素。首先，生物技术的进步为蛋白质药物的开发开闢了新的途径。重组DNA技术的日益普及便是例证，该技术能够生产出特异性和有效性更高的治疗性蛋白质。此外，癌症、糖尿病和自体免疫疾病等慢性疾病的发生率不断上升，也推动了对创新治疗方案的需求。因此，製药公司正在大力投资研发，以开发针对这些疾病的新型蛋白质疗法。此外，日本人口老化也是蛋白质疗法市场的重要驱动力。随着老龄人口的增长，对能够治疗与年龄相关疾病的疗法的需求也随之增加，这进一步刺激了对蛋白质药物的需求。此外，在预测期内，个人化医疗（根据个别患者客製化治疗方案）的新兴趋势预计将推动日本蛋白质疗法市场的发展。

日本蛋白质治疗市场细分：

产品洞察：

单株抗体（mAb）
人类胰岛素
促红血球生成素
凝血因子
融合蛋白
其他的

治疗领域见解：

代谢紊乱
免疫疾病
血液系统疾病
癌症
荷尔蒙失调
遗传性疾病
其他的

功能洞察：

酶促和调节活性
特殊目标活动
疫苗
蛋白质诊断

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本蛋白质治疗市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本蛋白质疗法市场有何影响？
日本蛋白质治疗市场依产品划分是怎样的？
日本蛋白质治疗市场依治疗领域划分是怎么样的？
日本蛋白质治疗市场根据功能如何划分？
日本蛋白质疗法市场的价值链分为哪些阶段？
日本蛋白质疗法的主要驱动因素和挑战是什么？
日本蛋白质治疗市场的结构是怎么样的？主要参与者是谁？
日本蛋白质治疗市场的竞争程度如何？

本报告回答的关键问题：

日本蛋白质治疗市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本蛋白质疗法市场有何影响？
日本蛋白质治疗市场依产品划分是怎样的？
日本蛋白质治疗市场依治疗领域划分是怎么样的？
日本蛋白质治疗市场根据功能如何划分？
日本蛋白质疗法市场的价值链分为哪些阶段？
日本蛋白质疗法的主要驱动因素和挑战是什么？
日本蛋白质治疗市场的结构是怎么样的？主要参与者是谁？
日本蛋白质治疗市场的竞争程度如何？

Japan protein therapeutics market size reached USD 30.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 53.8 Billion by 2033, exhibiting a growth rate (CAGR) of 6.27% during 2025-2033. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

Monoclonal Antibodies (mAbs)
Human Insulin
Erythropoietin
Clotting Factors
Fusion Protein
Others

Therapy Area Insights:

Metabolic Disorders
Immunological Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

Function Insights:

Enzymatic and Regulatory Activity
Special Targeting Activity
Vaccines
Protein Diagnostics

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan protein therapeutics market?
What is the breakup of the Japan protein therapeutics market on the basis of product?
What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
What is the breakup of the Japan protein therapeutics market on the basis of function?
What are the various stages in the value chain of the Japan protein therapeutics market?
What are the key driving factors and challenges in the Japan protein therapeutics?
What is the structure of the Japan protein therapeutics market and who are the key players?
What is the degree of competition in the Japan protein therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Protein Therapeutics Market - Breakup by Product

6.1 Monoclonal Antibodies (mAbs)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Human Insulin
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Erythropoietin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Clotting Factors
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Fusion Protein
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

7.1 Metabolic Disorders
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Immunological Disorders
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Hematological Disorders
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Cancer
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Hormonal Disorders
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Genetic Disorders
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Protein Therapeutics Market - Breakup by Function

8.1 Enzymatic and Regulatory Activity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Special Targeting Activity
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Vaccines
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Protein Diagnostics
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)

9 Japan Protein Therapeutics Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Protein Therapeutics Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis